The Compensation Committee of the Board of Directors of Ligand Pharmaceuticals Incorporated approved a promotion for Mr. Matthew Korenberg to Executive Vice President, Finance and Chief Financial Officer and for Mr. charles s. berkman to Senior Vice President, General Counsel and Secretary.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73.22 USD | +0.54% | +4.76% | +2.52% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.52% | 1.31B | |
+33.43% | 700B | |
+27.56% | 569B | |
-5.12% | 358B | |
+19.59% | 330B | |
+4.89% | 287B | |
+16.53% | 236B | |
+6.81% | 202B | |
-9.12% | 197B | |
+4.26% | 161B |
- Stock Market
- Equities
- LGND Stock
- News Ligand Pharmaceuticals Incorporated
- Ligand Pharmaceuticals Incorporated Announces Executive Changes